Zobrazeno 1 - 10
of 15
pro vyhledávání: '"S. V. Antunes"'
Autor:
Manuel Carcao, Brian M. Feldman, L. R. Brandao, Audrey Abad, Victor S. Blanchette, Jorge David Aivazoglou Carneiro, Paula Ribeiro Villaça, D Castro, S. V. Antunes, Margareth C. Ozelo, Nancy L. Young
Publikováno v:
Haemophilia : the official journal of the World Federation of Hemophilia. 23(5)
Introduction Although the regular replacement of clotting factor concentrates (prophylaxis) has been well established as the standard of care for severe haemophilia, the high cost of factor concentrates has limited access to prophylaxis in countries
Autor:
Margareth C. Ozelo, Loretta Buchner-Daley, S. V. Antunes, Audrey Abad, Krista Fischer, Paula Ribeiro Villaça, John D. Grainger, Ling Tang, Gilian Wharfe, Victor S. Blanchette, Jorge David Aivazoglou Carneiro, Carmen Altisent, Koyo Usuba, Nancy L. Young, Susanne Holzhauer, Victoria E. Price, Sandrine Meunier, Brian M. Feldman, Koon‐Hung Luke, Runhui Wu, Cindy Wakefield
Publikováno v:
Research and Practice in Thrombosis and Haemostasis, Vol 3, Iss 3, Pp 397-404 (2019)
Research and Practice in Thrombosis and Haemostasis
Research and practice in thrombosis and haemostasis, 3(3), 397
Research and Practice in Thrombosis and Haemostasis
Research and practice in thrombosis and haemostasis, 3(3), 397
Background Prophylaxis reduces the frequency of bleeds in boys with severe hemophilia and is the standard care for their management in resource-abundant countries. The effect of prophylaxis on Health-Related Quality of Life (HRQoL) has not been estab
Autor:
Areg Grigorian, Vasily Mamonov, S. V. Antunes, Norma Guzman-Becerra, S. Tangada, W.-Y. Wong, J. Phillips, Bruce M. Ewenstein, Oleksandra Stasyshyn
Publikováno v:
Haemophilia
Factor replacement therapy for the treatment of moderate to severe haemophilia A and B can be complicated by the production of inhibitory alloantibodies to factor VIII (FVIII) or factor IX. Treatment with the nanofiltered anti-inhibitor coagulant com
Autor:
Antonio Sérgio Alfredo Guimarães, Luis Garcia Alonso, S. V. Antunes, Camila L. Quaglio, Ricardo Luiz Smith, Thatiana B. Guimarães, Mariana Brandão Ferreira-Cabrini
Publikováno v:
International journal of odontostomatology v.9 n.2 2015
SciELO Chile
CONICYT Chile
instacron:CONICYT
SciELO Chile
CONICYT Chile
instacron:CONICYT
El objetivo fue investigar la prevalencia de trastornos temporomandibulares (TTM) entre pacientes hemofilicos A y B severos y moderados, y hombres sanos como grupo de control. Una complicacion de la Hemofilia es la artropatia cronica como resultado d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::34b3cd0b5553142a7beb8f1baa410001
http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0718-381X2015000200017
http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0718-381X2015000200017
Publikováno v:
Expert review of hematology. 8(3)
Inhibitor development is the most serious adverse event linked to the treatment of hemophilia, as it renders standard hemostatic therapy ineffective. Consequently, inhibitor patients are at increased risk for difficult-to-control bleeding and complic
Publikováno v:
Haemophilia. 9:573-577
Intracranial haemorrhage (ICH) is a common cause of morbidity and mortality in haemophilic patients. The overall incidence of ICH has been reported to range from 2.2% to 7.5% in patients with haemophilia. From 1987 to 2001, 401 haemophilic patients f
Autor:
S. V. Antunes
Publikováno v:
Haemophilia. 8:199-204
The success of haemophilia treatment is based on well-established criteria, and the use of clotting factor concentrates is fundamental. These strategies are seen in the developed world when measures of quality of life are studied or when disabilities
Publikováno v:
Haemophilia : the official journal of the World Federation of Hemophilia. 20(5)
Summary The Pro-FEIBA study reported health-related quality of life (HRQoL) improved following 6-month of Factor Eight Inhibitor Bypassing Activity (FEIBA) prophylaxis. This study investigates whether 12-month of FEIBA prophylaxis improved HRQoL in h
Autor:
Maria Stella Figueiredo, Maria de Lourdes Lopes Ferrari Chauffaille, S. V. Antunes, R. Beltrani, José Kerbauy, Mihoko Yamamoto
Publikováno v:
Brazilian Journal of Medical and Biological Research v.34 n.6 2001
Brazilian Journal of Medical and Biological Research
Associação Brasileira de Divulgação Científica (ABDC)
instacron:ABDC
Brazilian Journal of Medical and Biological Research, Vol 34, Iss 6, Pp 735-743 (2001)
Repositório Institucional da UNIFESP
Universidade Federal de São Paulo (UNIFESP)
instacron:UNIFESP
Brazilian Journal of Medical and Biological Research, Volume: 34, Issue: 6, Pages: 735-743, Published: JUN 2001
Brazilian Journal of Medical and Biological Research
Associação Brasileira de Divulgação Científica (ABDC)
instacron:ABDC
Brazilian Journal of Medical and Biological Research, Vol 34, Iss 6, Pp 735-743 (2001)
Repositório Institucional da UNIFESP
Universidade Federal de São Paulo (UNIFESP)
instacron:UNIFESP
Brazilian Journal of Medical and Biological Research, Volume: 34, Issue: 6, Pages: 735-743, Published: JUN 2001
Acute promyelocytic leukemia (AML M3) is a well-defined subtype of leukemia with specific and peculiar characteristics. Immediate identification of t(15;17) or the PML/RARA gene rearrangement is fundamental for treatment. The objective of the present
Publikováno v:
Haemophilia : the official journal of the World Federation of Hemophilia. 14(1)